Lucentis Approval For Wet AMD Includes Less Frequent Dosing Option
Executive Summary
FDA's June 30 approval of Genentech's Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration includes the possibility for less frequent, quarterly dosing
You may also be interested in...
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady
Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics
Avastin Experience Clarifies FDA Concerns With Cooperative Group Trials
FDA's concern with oncologic trials conducted by cooperative groups appears to be focused on the use of progression-free survival as an endpoint, according to Genentech Product Development President Susan Desmond-Hellman